High-salt diet may drive fatty liver disease differently in lean people
· Medical Xpressedited by Swati Mestri, reviewed by Robert Egan
Swati Mestri
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Fatty liver disease is commonly associated with obesity, yet a growing number of people with normal body weight develop a severe form of the condition. Scientists at Duke-NUS Medical School have identified a distinct mechanism in a mouse model that may help explain why: Excess dietary salt can alter liver metabolism and trigger inflammatory pathways associated with lean metabolic dysfunction-associated steatohepatitis (MASH).
The findings, published in Molecular Metabolism, could help explain why treatments designed for obesity-associated MASH may not work as well in lean patients and point toward more tailored approaches to diagnosis and treatment.
The puzzle of lean MASH
MASH is a progressive, severe form of liver disease marked by persistent inflammation and tissue scarring. Left untreated, the condition can advance to liver failure, cirrhosis and liver cell cancer. MASH is increasingly common, particularly in Singapore and other westernized Asian populations, with an estimated prevalence of up to 40%.
A growing proportion of people around the world, particularly in Asian populations, have developed MASH despite maintaining a normal body mass index—hence the term "lean MASH." The environmental triggers and molecular mechanisms underlying lean MASH remain unclear, and there are no suitable laboratory models to study the disease.
Salt reshapes liver metabolism
To address these challenges, the scientists developed the world's first diet-induced mouse model of lean MASH. The model mirrors key features of lean MASH, including relatively low levels of liver fat but severe inflammation and scarring. This reflects a pattern seen in some patients, who may have less liver fat but face a higher risk of serious liver complications and death.
The team, which included researchers from Duke-NUS, National Heart Centre Singapore, Duke University School of Medicine and University College London, also discovered that excess dietary salt changes how the liver handles fat—increasing fat breakdown while activating immune cells that drive inflammation in the liver.
"Our findings suggest that lean MASH is not simply the same disease occurring in a thinner person. The biology appears to be different. While obesity-associated MASH is closely linked to excess fat accumulation, our model shows that high dietary salt can alter liver metabolism and activate inflammatory pathways even without obesity.
That distinction matters because treatments developed for obesity-associated MASH may not address what is driving disease in lean patients," explained Dr. Zhou Jin, lead author of the study. She is also a principal research scientist at Duke-NUS' Cardiovascular & Metabolic Disorders Signature Research Programme and a Gilead Research Scholar.
Beyond the liver
Because cardiovascular disease is a primary cause of death among MASH patients, establishing a relevant experimental model could have implications beyond liver health.
Derek John Hausenloy, a professor in the Cardiovascular & Metabolic Disorders Signature Research Programme at Duke-NUS Medical School and one of the study's authors, said, "This model gives us a way to investigate and understand lean MASH as a whole-body disease, not just a liver condition. That is particularly important because cardiovascular disease is a leading cause of death in patients with MASH. We can now begin to ask whether the mechanisms driving liver injury in lean MASH also affect the heart."
Toward tailored diagnosis and treatment
Lok Shee-Mei, a professor and vice dean of the Office of Research at Duke-NUS, said, "This study challenges the assumption that fatty liver disease follows the same biological pathway in every patient. By revealing a distinct mechanism in lean MASH, and providing a preclinical model with which to study it, the team has created an important foundation for developing diagnostics and treatments that reflect the biology of the individual patients."
The team will next use this model to identify early diagnostic biomarkers of lean MASH and test compounds that can selectively block salt-induced inflammatory pathways identified in the study. Ultimately, this could help clinicians distinguish lean MASH earlier and determine which treatments are most likely to benefit individual patients.
Publication details
Shaopeiwen Luo et al, High salt supplementation of a MASH-inducing diet causes lean MASH phenotype with increased hepatic urea cycle activity and EIF5A hypusination, Molecular Metabolism (2026). DOI: 10.1016/j.molmet.2026.102417
Journal information: Molecular Metabolism
Clinical categories
GastroenterologyCommon illnesses & PreventionNutrition & Healthy eatingHealthy living Provided by Duke-NUS Medical School Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: High-salt diet may drive fatty liver disease differently in lean people (2026, September 28) retrieved 28 September 2026 from https://medicalxpress.com/news/2026-09-high-salt-diet-fatty-liver.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.